Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.
News|Videos|April 8, 2026
Q1 2026 Recap: Hepatology News and Updates
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
Q1 2026 hepatology highlights include advances in MASH, hepatitis B, gene editing for AATD, and the first approved therapy for pruritus in PBC.
Advertisement
Advertisement
The first quarter of 2026 brought a wave of momentum in hepatology, with advances spanning metabolic liver disease, viral hepatitis, rare genetic disorders, and symptom-directed care. From regulatory designations to late-stage clinical data and US Food and Drug Administration (FDA) approvals, the landscape continues to evolve rapidly, with a growing emphasis on disease modification and precision-based approaches.
Related to this article
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
Hepatology in Q3 2026: brelovitug and lonafarnib advance in hepatitis D, plus Wilson disease, MASH, and US alcohol use updates.
Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.
Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.
A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.
Advertisement
Advertisement